SCHEMBL4721713

SCHEMBL4721713

CCCCN(CCCC)C1[C]Oc2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
USP2 O75604 1/20 0.33
OPRM1 P35372 1/20 0.32
OPRL1 P41146 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724912 0.97 KMT2A (0.38) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4723731 0.95 KMT2A (0.36) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4722732 0.90 MEN1 (0.42) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4720879 0.86 KMT2A (0.36) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4723614 0.86 MEN1 (0.41) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4723298 0.85 KMT2A (0.35) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4765769 0.83 MEN1 (0.39) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4720693 0.82 KMT2A (0.37) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4722148 0.81 KMT2A (0.35) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4723855 0.79 MEN1 (0.41) KMT2AMEN1TSHRSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 KMT2A 3345/4885MEN1 4451/4885TSHR 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.